Legend Biotech Investor Presentation — May 2024

Document content

Corporate UpdateMay 13, 2024

This presentation is for investor relations purposes only - Not for product promotional purposesForward -looking Statements

This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the

“Company”) solely for information purpose and does not contain all relevant information

relating to the Company.

The safety and efficacy of the agents and/or uses under investigation discussed in this

presentation have not been established, except to the extent specifically provided by marketing

authorizations previously received from relevant health authorities. Further, for investigational

agents and/or uses, the Company cannot guarantee health authority approval or that such

agents and/or uses will become commercially available in any country.

Certain information contained in this presentation and statements made orally during this

presentation relate to or are based on studies, publications, surveys and other data obtained

from third -party sources and Legend Biotech's own internal estimates and research. While

Legend Biotech believes these third -party sources to be reliable as of the date of this

presentation, it has not independently verified, and makes no representation as to the

adequacy, fairness, accuracy or completeness of, any information obtained from third -party

sources. While Legend Biotech believes its internal research is reliable, such research has not

been verified by any independent source.

Statements in this presentation about future expectations, plans and prospects, as well as any

other statements regarding matters that are not historical facts, constitute “forward -looking

statements” within the meaning of The Private Securities Litigation Reform Act of 1995.

These statements include, but are not limited to, statements relating to Legend Biotech’s

strategies and objectives; statements relating to CARVYKTI® (ciltacabtagene autoleucel ; cilta -

cel), including patient population of CARVYKTI®, Legend Biotech’s expectations for

CARVYKTI®, including manufacturing expectations for CARVYKTI®; and statements about

regulatory submissions for CARVYKTI®, and the progress of such submissions with the FDA,

the EMA and other regulatory authorities; and expected results and timing of clinical trials;

Legend Biotech’s expectations for LB2102 and its potential benefits; the potential benefits of the licensing transaction; Legend Biotech’s expectations on advancing their pipeline and

product portfolio; and the potential benefits of Legend Biotech’s product candidates. The words